SFPM(SZ:002737)2023-04-27 16:00Revenue and Profit - The company's revenue for Q1 2023 was CNY 1,765,521,894.46, representing a 47.31% increase compared to CNY 1,198,471,522.45 in the same period last year[14]. - Net profit attributable to shareholders was CNY 406,135,072.45, an increase of 85.30% from CNY 219,172,003.91 year-over-year[14]. - The net profit after deducting non-recurring gains and losses was CNY 390,404,960.30, reflecting a 92.25% increase compared to CNY 203,076,117.89 in the previous year[14]. - The net profit for the first quarter was CNY 435,364,881.11, representing an increase from CNY 234,304,233.39 in the previous year, which is a growth of approximately 86%[38]. - The total revenue for the quarter was CNY 514,911,099.53, compared to CNY 286,565,292.81 in the same period last year, indicating a year-over-year increase of about 79.5%[38]. - Basic earnings per share increased to CNY 0.70, up 84.21% from CNY 0.38 in the previous year[14]. - The basic and diluted earnings per share were both CNY 0.70, up from CNY 0.38 in the previous year, reflecting an increase of 84.2%[38]. Cash Flow and Assets - The company's cash flow from operating activities was CNY 249,028,652.64, down 42.17% from CNY 430,597,673.80 in the same period last year[14]. - Net cash flow from operating activities decreased by 42.2% to ¥249,028,652.64, down from ¥430,597,673.80, mainly due to increased cash payments for goods and services[29]. - Cash inflow from investment activities was $252,569,927.27, compared to $355,539,307.25 in the previous period, reflecting a decrease of 29.0%[50]. - Cash outflow for operating activities totaled $1,464,236,440.00, which is a 38.6% increase from $1,055,974,047.54 in the previous period[50]. - The company's total assets amounted to ¥7,111,948,904.92, compared to ¥7,031,765,675.45 in the same period last year[37]. - The total assets of the company reached CNY 7,111,948,904.92, compared to CNY 7,031,765,675.45 at the end of the previous year, showing a slight increase of approximately 1.1%[46]. - Cash and cash equivalents at the end of the period were CNY 2,850,259,526.27, up from CNY 1,758,239,735.95, marking an increase of about 62.1%[40]. Liabilities and Equity - Total assets at the end of the reporting period were CNY 7,111,948,904.92, a 1.14% increase from CNY 7,031,765,675.45 at the end of the previous year[14]. - Shareholders' equity attributable to the parent company increased by 9.84% to CNY 4,618,437,870.45 from CNY 4,204,751,036.78[14]. - The total liabilities amounted to CNY 2,230,315,881.43, down from CNY 2,593,018,932.11, indicating a decrease of approximately 13.9%[46]. - The company’s equity attributable to shareholders was CNY 584,000,000.00, unchanged from the previous year[46]. Expenses and Financial Performance - Operating costs rose to ¥714,027,194.57, reflecting a 46.3% increase from ¥487,891,887.11 in the previous year, driven by sales growth[29]. - R&D expenses increased by 47.6% to ¥21,168,133.51, up from ¥14,338,611.92, attributed to the progress of R&D projects[29]. - The company’s net profit for the period increased, leading to a 51.4% rise in income tax expenses to ¥79,415,781.39 from ¥52,465,396.81[29]. - Financial expenses showed a negative value of -¥5,565,071.31, reflecting a 114.3% increase in interest income compared to the previous year[29]. Other Developments - The company did not report any new product developments or market expansion strategies during this quarter[20]. - The company decided to deregister its wholly-owned subsidiary, Harbin New Kui Pharmaceutical Technology Co., Ltd., during the reporting period[44]. - The company reported a significant decrease in contract liabilities by 74.20%, from ¥551,542,218.53 to ¥142,315,162.92, due to revenue recognition based on performance progress[29].